Business: Phase 3 biotech developing small molecule therapies for Alzheimer's disease. Centrexion Therapeutics - Boston, 5 million shares, priced ...
News
- Initial public offerings scheduled to debut next week
- Fortress Biotech: 3Q Earnings Snapshot
NEW YORK (AP) _ Fortress Biotech Inc. (FBIO) on Friday reported a loss of $16.6 million in its third quarter. On a per-share basis, the New York-based ...
- Bio Roundup: Midterm Fallout, Alzheimer's Search, Postpartum Panel
A prize in San Antonio will focus on ideas that explain the cause of Alzheimer's, ... —An experimental rosacea treatment from Israeli biotech Foamix ...
- Vietnam and Cuba sign trade agreement, pledge to deepen ties
... and enhance cooperation in agriculture, biotechnology, the pharmaceutical sector, medicine, education, science and people-to-people exchanges.
- FibroGen: 3Q Earnings Snapshot
The biotech drug developer posted revenue of $29 million in the period, which also did not meet Street forecasts. Three analysts surveyed by Zacks ...